Stopping azithromycin mass drug administration for trachoma: A systematic review.
The World Health Organization (WHO) recommends continuing azithromycin mass drug administration (MDA) for trachoma until endemic regions drop below 5% prevalence of active trachoma in children aged 1-9 years. Azithromycin targets the ocular strains of Chlamydia trachomatis that cause trachoma. Regio...
Guardado en:
Autores principales: | Hamidah Mahmud, Emma Landskroner, Abdou Amza, Solomon Aragie, William W Godwin, Anna de Hostos Barth, Kieran S O'Brien, Thomas M Lietman, Catherine E Oldenburg |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/00a67f0c27c84c1b908259ee1f956be2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Prevalence of trachoma at sub-district level in ethiopia: determining when to stop mass azithromycin distribution.
por: Jonathan D King, et al.
Publicado: (2014) -
Mass treatment with azithromycin for trachoma control: participation clusters in households.
por: Elizabeth N Ssemanda, et al.
Publicado: (2010) -
Surveillance for peri-elimination trachoma recrudescence: Exploratory studies in Ghana.
por: Laura Senyonjo, et al.
Publicado: (2021) -
Comparing the performance of cluster random sampling and integrated threshold mapping for targeting trachoma control, using computer simulation.
por: Jennifer L Smith, et al.
Publicado: (2013) -
Environmental factors and hygiene behaviors associated with facial cleanliness and trachoma in Kongwa, Tanzania.
por: Xinyi Chen, et al.
Publicado: (2021)